The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Partner with us for Guaranteed Bulk Supply

Whether you need a human biomarker, functional enzyme or highly specific nanobody, we’re able to develop, produce and scale-manufacture your protein of interest and validate it for a range of different end-user applications. For more details on what we offer, see our information below or get in touch with a member of our team.

Bulk Protein Production

The Native Antigen Company has over 10 years of experience supplying bulk reagents to the diagnostic, pharmaceutical and biotechnology industries. We offer gram-scale production from a range of established expression systems and are able to develop proteins in-house as well as support your ongoing manufacturing processes.

Our VirtuE™ (HEK293) system is ideal for yielding native-like post-translational modifications and proper folding of human proteins to maximise performance in assays. To accommodate the breadth of customers requests, we also offer insect-baculovirus, E. coli and native culture of both viruses and bacteria.

Bulk Protein Production Workflow

Partner with us to take advantage of our core strengths:

‣  Quality

Our decades of expertise in expression and purification ensure that each of our proteins is produced to the highest standards. Traceable from manufacture through to delivery, our processes ensure a high level of confidence in the quality and reproducibility of our products. All of our operations adhere to ISO9001 standards, thereby meeting the requirements of ISO13485 or GMP systems for their raw materials to be manufactured to recognised quality standards. We also welcome customer audits, and requests for documentation and further validation.

‣  Flexibility

In addition to our range of expression systems, we offer extensive custom specifications and post-production testing. These include, the introduction of tags, secretion signals and mutations, as well as downstream endotoxin, stability, and bioactivity testing. For more information on our vector design, protein purification, antibody generation and assay development services, see our Contract Services.

‣  Agility

With years of experience in responding to emergent viral pathogens, we understand what it means to be agile. To maximise project success and speed to market for our customers, our R&D team can parallelise multiple feasibility studies, followed by accelerated scale manufacture and purification with a range of different methods.

Bulk Antibody Production

The Native Antigen Company offers bulk production of recombinant antibodies to multi-gram scales. Our capabilities include the production of both IgG and pentameric IgM chimeras, as well as various antibody fragments from our proprietary VirtuE™ HEK293 expression system.

For antibody discovery and generation, we offer immunisation services for the development of monoclonal hybridomas, followed by sequencing and transfer to recombinant systems. Our processes are highly batch consistent to ensure reproducible results for our customers in a range of applications, from fundamental research to drug discovery and IVD development. We also offer a range of custom services, including class- and isotype-switching, affinity/avidity and functionality testing, and bulk conjugation to meet your specific needs.

Get in Touch with a Member of our Team

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

10 + 12 =

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

New antigens support research into BA.5 variant, currently responsible for over half of global COVID-19 cases Oxford, UK, 02 November 2022: The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Preparing for Disease Y: A Better Serological Toolbox

This article was originally published on Clinical Lab Manager. It’s been over a year since the World Health Organization (WHO) declared COVID-19 a pandemic. SARS-CoV-2 has since infected 200 million people, resulting in nearly 4 million deaths and substantial economic...

Keeping Up with the New SARS-CoV-2 Variant Nomenclature

If you’ve been struggling to make sense of SARS-CoV-2 variant nomenclature, you’re not alone. Due to the existence of multiple genomic sequence databases, various naming systems are in use for the rapidly growing range of SARS-CoV-2 variants of concern/interest. In a...

Making Sense of the SARS-CoV-2 Spike Mutations

Through much of 2020, SARS-CoV-2 accumulated mutations at a steady, yet unspectacular rate. However, as global cases approached 100 million by the end of the year, multiple variants began to emerge. Exhibiting more considerable genomic changes, some variants have...

D614G: Putting the Mutation in Perspective

Since the emergence of SARS-CoV-2, scientists have speculated about the risks of mutation and what this could mean for therapeutics and vaccines. In this blog, we explore the nature viral mutation, what is known about the D614G mutant of SARS-CoV-2, and introduce our...

The Endemic Coronaviruses and What They Might Tell us About COVID-19

While less-well known than some of their counterparts, the 229E, NL63, OC43, and HKU1 human coronaviruses are a significant cause of respiratory disease worldwide. The evolutionary histories and host associations of the endemic coronaviruses also provide important...

Q&A: An Insight Into COVID-19 Serology

During the course of the current coronavirus pandemic, we have all been aware of the urgent need for nucleic acid testing to identify people currently infected with SARS-CoV-2. The second form of testing needed are serological immunoassays, which can identify past...

A Q&A with David Flavell of Leukaemia Busters

In this blog, we speak with Dr. David Flavell about his scientific career, the legacy of Leukaemia Busters, and the recent impact that COVID-19 has had on his research.Tell me about your scientific background David. I was born in a seaside town called Southport in the...

Avoiding the Immunopathology Pitfalls of a COVID-19 Vaccine

In the second of a three-part series on COVID-19 vaccines, we explore the potential challenges in stimulating safe vaccine responses and outline the role that diagnostics will play in guiding their development.Rogue Responses Antibodies play a crucial role in...

Designing for Differentiation: Why We Need Highly Specific Diagnostics for a COVID-19 Vaccine

Assessment of vaccine-induced immune responses in clinical trials will require highly specific diagnostic assays to ensure safety. This blog was originally published on Clinical Lab Manager.The Vaccine Race Vaccines are the most effective means of preventing...

An Early Look at Vaccines for COVID-19

In the first of a three-part series on the design, immunology and manufacture of COVID-19 vaccines, we take an early look at the major technologies under development and weigh-up the challenges these vaccines will face in reaching late-phase clinical trials.Why We...

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

Coronaviruses: The Next Disease X?

For much of their known history, the coronaviruses were regarded as relatively benign pathogens with little potential to cause human harm. However, the emergence of SARS and MERS in recent decades has brought coronaviruses into the global spotlight. In this blog we...